Ashique Sumel, Mishra Neeraj, Garg Ashish, Kumar Nitish, Khan Zuber, Mohanto Sourav, Chellappan Dinesh Kumar, Farid Arshad, Taghizadeh-Hesary Farzad
Department of Pharmaceutical Sciences, Bengal College of Pharmaceutical Sciences & Research, Durgapur 713212, West Bengal, India.
Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior 474005, MP, India.
Arch Bronconeumol. 2024 Oct;60 Suppl 2:S46-S58. doi: 10.1016/j.arbres.2024.04.030. Epub 2024 May 6.
Lung cancer remains the leading cause of cancer-related deaths worldwide. According to the American Cancer Society (ACS), it ranks as the second most prevalent type of cancer globally. Recent findings have highlighted bidirectional gut-lung interactions, known as the gut-lung axis, in the pathophysiology of lung cancer. Probiotics are live microorganisms that boost host immunity when consumed adequately. The immunoregulatory mechanisms of probiotics are thought to operate through the generation of various metabolites that impact both the gut and distant organs (e.g., the lungs) through blood. Several randomized controlled trials have highlighted the pivotal role of probiotics in gut health especially for the prevention and treatment of malignancies, with a specific emphasis on lung cancer. Current research indicates that probiotic supplementation positively affects patients, leading to a suppression in cancer symptoms and a shortened disease course. While clinical trials validate the therapeutic benefits of probiotics, their precise mechanism of action remains unclear. This narrative review aims to provide a comprehensive overview of the present landscape of probiotics in the management of lung cancer.
肺癌仍然是全球癌症相关死亡的主要原因。根据美国癌症协会（ACS）的数据，它是全球第二大常见癌症类型。最近的研究结果强调了肠道与肺部之间的双向相互作用，即所谓的肠-肺轴，在肺癌病理生理学中的作用。益生菌是一类活的微生物，适量摄入时可增强宿主免疫力。益生菌的免疫调节机制被认为是通过产生各种代谢产物来实现的，这些代谢产物通过血液影响肠道和远处器官（如肺部）。几项随机对照试验强调了益生菌在肠道健康中的关键作用，特别是在预防和治疗恶性肿瘤方面，尤其侧重于肺癌。目前的研究表明，补充益生菌对患者有积极影响，可导致癌症症状得到抑制，病程缩短。虽然临床试验证实了益生菌的治疗益处，但其确切作用机制仍不清楚。这篇叙述性综述旨在全面概述益生菌在肺癌管理中的现状。
